日本全国前瞻性队列调查中辉瑞BNT162b2、莫德纳mRNA-1273与阿斯利康AZD1222在SARS-CoV-2疫苗接种初期的安全性比较
本研究于2021年2月在112家政府医院及顺天堂大学医院开展,针对SARS-CoV-2疫苗基础免疫程序,比较辉瑞、莫德纳和阿斯利康疫苗的征集性不良事件发生时间及非征集性不良事件患病率。辉瑞和莫德纳mRNA疫苗第二剂后发热频率高于第一剂,阿斯利康病毒载体疫苗第一剂后副作用更频繁。尽管三种疫苗不良事件发生率按年龄和性别存在差异,所有疫苗耐受性良好。
要点
- mRNA疫苗第二剂后发热频率高于第一剂,阿斯利康疫苗第一剂后副作用更频繁。
- 全身性不良事件(含体温≥37.5°C发热)发生率莫德纳最高,其次阿斯利康,辉瑞最低。
- 女性不良事件频率高于男性;全身反应随年龄增加而减少,阿斯利康年龄效应最明显。
核心结论
- 尽管三种疫苗不良事件发生率按年龄和性别存在差异,所有疫苗耐受性良好。
- 这些发现提供关键安全性信息,支持知情疫苗接种决策和持续监测工作。
研究设计与样本
- 本研究为全国性大规模前瞻性队列研究,于2021年2月在112家政府医院及顺天堂大学医院开展,针对SARS-CoV-2疫苗基础免疫程序。
主要发现
- 辉瑞和莫德纳mRNA疫苗第二剂后发热频率高于第一剂,阿斯利康病毒载体疫苗第一剂后副作用更频繁。
- mRNA疫苗副作用最常见于接种后第二天,到第四天几乎消退。
- 全身性不良事件(包括体温≥37.5°C发热)发生率莫德纳最高,其次阿斯利康,辉瑞最低。
- 阿斯利康疫苗局部反应频率低于辉瑞和莫德纳疫苗,但持续时间趋向更长。
- 女性不良事件频率高于男性;全身反应随年龄增加的比值比(校正性别)阿斯利康最小,其次辉瑞和莫德纳(<1),表明随年龄增加发热和全身反应频率下降更明显,年龄效应因疫苗而异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study was conducted at 112 government and Juntendo University hospitals in February 2021 for the primary series of SARS-CoV-2 vaccinations. We compared the timing of solicited adverse event (AE) onset and prevalence of unsolicited AEs for Pfizer, Moderna, and AstraZeneca vaccines in a nationwide, large-scale prospective cohort study. The Pfizer and Moderna mRNA vaccines were associated with a higher frequency of fever after the second dose than after the first dose. The AstraZeneca viral vector vaccine resulted in more frequent side effects after the first dose. The side effects of mRNA vaccines were the most common on the day after vaccination and almost subsided by the fourth day. The incidence of systemic AEs, including fever of ≥37.5 °C, was the highest for Moderna, followed by AstraZeneca and Pfizer. Local reactions were less frequent with the AstraZeneca vaccine than with the Pfizer and Moderna vaccines but tended to last longer. The frequency of AEs was higher in women than in men. The odds ratio for age per year regarding systemic reactions (adjusted for sex) was the least for AstraZeneca, followed by Pfizer and Moderna (< 1), indicating a more pronounced decrease in the frequency of fever and systemic reactions with increasing age. Age effects varied among vaccines. Delayed skin reactions, appearing around the seventh day after the first dose (Day 8), were observed as itchy redness, particularly in women aged ≥30 with the Moderna vaccine and less often with the Pfizer vaccine. Over half of the delayed skin reactions involved local erythema immediately after the second dose, but these reactions mostly disappeared within approximately 10 days. Despite differences in the incidence of AEs among the three vaccines by age and sex, all vaccines were well-tolerated. These findings provide crucial safety information, supporting informed vaccination decisions and ongoing surveillance efforts.
引用
- Ito S, Tsuchida N, Kusunoki S, et al. Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan. Vaccine. 2025. PMID: 39879847. doi:10.1016/j.vaccine.2025.126754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。